Epidiolex Clinical Review Timeline
Chronicle of the development and US FDA review of GW Pharmaceutical's Epidiolex (cannabidiol) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients ages 2 and older.
You may also be interested in...
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.